{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:06:25Z","timestamp":1773277585650,"version":"3.50.1"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The applicability of immunotherapy would be dramatically broadened to a greater number of recipients if direct \u201coff-the-shelf\u201d products could be engineered to engender functionally potent immune responses against true \u201cself\u201d-tumor antigens. This would obviate the need for ex vivo culture of dendritic cells or T cells on a patient-by-patient basis, for example. The carcinoembryonic antigen (CEA) is a glycoprotein expressed in normal gut epithelium that is up-regulated in the majority of colon cancers, non-small cell lung cancers, and half of all breast cancers. Such properties make CEA an excellent and important target for cancer immunotherapy. In this study, we show stabilization of 14-day established s.c. mGC4CEA tumors in human CEA (huCEA) transgenic mice following two direct low-dose injections of 0.15 \u00d7 106 transducing units of a lentiviral vector (LV) that directs expression of huCEA (LV-huCEA). This stabilization result was reproducible and detailed analyses including antibody assays, multiplex cytokine analyses on unstimulated splenocytes, lymph node cell characterizations, tetramer staining, and immunofluorescence staining of tumor sections showed that this outcome correlated with both a cellular and humoral immune response. Similar tumor outcomes were not seen when mice were vaccinated with a control LV that engineered expression of enGFP only. The long-term potency of this vaccination strategy was also studied and revealed the requirement for maintenance of tumor antigen-specific immunity for efficient tumor control. These data support the use of direct injections of low doses of LV-huCEA for enhancement of tumor immunotherapy directed against CEA. [Mol Cancer Ther 2009;8(3):OF692\u201311]<\/jats:p>","DOI":"10.1158\/1535-7163.mct-08-0769","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T01:47:23Z","timestamp":1236736043000},"page":"692-702","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection"],"prefix":"10.1158","volume":"8","author":[{"given":"Severine","family":"Loisel-Meyer","sequence":"first","affiliation":[{"name":"1Ontario Cancer Institute and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Felizardo","sequence":"additional","affiliation":[{"name":"1Ontario Cancer Institute and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Mariotti","sequence":"additional","affiliation":[{"name":"5Experimental Transplantation and Immunology Branch and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam E.","family":"Mossoba","sequence":"additional","affiliation":[{"name":"5Experimental Transplantation and Immunology Branch and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Foley","sequence":"additional","affiliation":[{"name":"5Experimental Transplantation and Immunology Branch and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kammerer","sequence":"additional","affiliation":[{"name":"6Tumor Immunology Laboratory, LIFE-Center, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany;"},{"name":"7Institute fur Immunologie, Friedrich-Loeffler-Institut, Tubingen, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Mizue","sequence":"additional","affiliation":[{"name":"1Ontario Cancer Institute and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Keefe","sequence":"additional","affiliation":[{"name":"8Lentigen Corporation, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Andrea","family":"McCart","sequence":"additional","affiliation":[{"name":"2Toronto General Research Institute, University Health Network;"},{"name":"4Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"6Tumor Immunology Laboratory, LIFE-Center, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boro","family":"Dropulic","sequence":"additional","affiliation":[{"name":"8Lentigen Corporation, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"5Experimental Transplantation and Immunology Branch and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[{"name":"1Ontario Cancer Institute and"},{"name":"2Toronto General Research Institute, University Health Network;"},{"name":"3Department of Medical Biophysics and"},{"name":"4Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2009,3,13]]},"reference":[{"key":"2022060801183960700_BIB1","doi-asserted-by":"crossref","unstructured":"Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines\u20082006;5:717\u201332.","DOI":"10.1586\/14760584.5.5.717"},{"key":"2022060801183960700_BIB2","doi-asserted-by":"crossref","unstructured":"Loisel-Meyer S, Foley R, Medin JA. Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci\u20082008;13:3202\u201314.","DOI":"10.2741\/2921"},{"key":"2022060801183960700_BIB3","doi-asserted-by":"crossref","unstructured":"He Y, Zhang J, Mi Z, Robbins P, Falo LD, Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol\u20082005;174:3808\u201317.","DOI":"10.4049\/jimmunol.174.6.3808"},{"key":"2022060801183960700_BIB4","doi-asserted-by":"crossref","unstructured":"Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapy strategy. Cancer Immunol Immunother\u20082006;55:1011\u20136.","DOI":"10.1007\/s00262-005-0095-5"},{"key":"2022060801183960700_BIB5","doi-asserted-by":"crossref","unstructured":"Mossoba ME, Walia JS, Rasaiah VI, et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther\u20082008;16:607\u201317.","DOI":"10.1038\/sj.mt.6300390"},{"key":"2022060801183960700_BIB6","doi-asserted-by":"crossref","unstructured":"Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res\u20082004;64:1490\u20135.","DOI":"10.1158\/0008-5472.CAN-03-2780"},{"key":"2022060801183960700_BIB7","doi-asserted-by":"crossref","unstructured":"Compte M, Banco B, Serrano F, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA \u00d7 anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther\u20082007;14:380\u20138.","DOI":"10.1038\/sj.cgt.7701021"},{"key":"2022060801183960700_BIB8","doi-asserted-by":"crossref","unstructured":"Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther\u20082007;14:847\u201362.","DOI":"10.1038\/sj.gt.3302947"},{"key":"2022060801183960700_BIB9","doi-asserted-by":"crossref","unstructured":"VandenDriessche T, Thorrez L, Naldini L, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood\u20082002;100:813\u201322.","DOI":"10.1182\/blood.V100.3.813"},{"key":"2022060801183960700_BIB10","doi-asserted-by":"crossref","unstructured":"Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest\u20082003;111:1673\u201381.","DOI":"10.1172\/JCI200317098"},{"key":"2022060801183960700_BIB11","doi-asserted-by":"crossref","unstructured":"Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther\u20082006;13:630\u201340.","DOI":"10.1038\/sj.gt.3302697"},{"key":"2022060801183960700_BIB12","doi-asserted-by":"crossref","unstructured":"Kim JH, Majumder N, Lin H, Watkins S, Falo LD, Jr, You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther\u20082005;16:1255\u201366.","DOI":"10.1089\/hum.2005.16.1255"},{"key":"2022060801183960700_BIB13","doi-asserted-by":"crossref","unstructured":"Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol\u20082002;20:2197\u2013207.","DOI":"10.1200\/JCO.2002.08.017"},{"key":"2022060801183960700_BIB14","unstructured":"Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol\u20082000;27:112\u20139."},{"key":"2022060801183960700_BIB15","doi-asserted-by":"crossref","unstructured":"Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res\u20082006;12:3064\u20139.","DOI":"10.1158\/1078-0432.CCR-05-2788"},{"key":"2022060801183960700_BIB16","doi-asserted-by":"crossref","unstructured":"Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol\u20082005;23:720\u201331.","DOI":"10.1200\/JCO.2005.10.206"},{"key":"2022060801183960700_BIB17","doi-asserted-by":"crossref","unstructured":"Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol\u20082000;18:3964\u201373.","DOI":"10.1200\/JCO.2000.18.23.3964"},{"key":"2022060801183960700_BIB18","doi-asserted-by":"crossref","unstructured":"Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res\u20082005;11:3017\u201324.","DOI":"10.1158\/1078-0432.CCR-04-2172"},{"key":"2022060801183960700_BIB19","unstructured":"Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res\u20081994;54:4169\u201376."},{"key":"2022060801183960700_BIB20","doi-asserted-by":"crossref","unstructured":"Nockel J, van den Engel NK, Winter H, Hatz RA, Zimmermann W, Kammerer R. Characterization of gastric adenocarcinoma cell lines established from CEA424\/SV40 T antigen-transgenic mice with or without a human CEA transgene. BMC Cancer\u20082006;6:57.","DOI":"10.1186\/1471-2407-6-57"},{"key":"2022060801183960700_BIB21","doi-asserted-by":"crossref","unstructured":"Cusi MG, Del Vecchio MT, Terrosi C, et al. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J Immunol\u20082005;174:7210\u20136.","DOI":"10.4049\/jimmunol.174.11.7210"},{"key":"2022060801183960700_BIB22","doi-asserted-by":"crossref","unstructured":"Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A\u20082006;103:17372\u20137.","DOI":"10.1073\/pnas.0608138103"},{"key":"2022060801183960700_BIB23","unstructured":"Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res\u20081998;58:3491\u20134."},{"key":"2022060801183960700_BIB24","unstructured":"Hung CF, Cheng WF, He L, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res\u20082003;63:2393\u20138."},{"key":"2022060801183960700_BIB25","doi-asserted-by":"crossref","unstructured":"Pilon SA, Piechocki MP, Wei WZ. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol\u20082001;167:3201\u20136.","DOI":"10.4049\/jimmunol.167.6.3201"},{"key":"2022060801183960700_BIB26","doi-asserted-by":"crossref","unstructured":"Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer\u20082004;109:499\u2013506.","DOI":"10.1002\/ijc.11696"},{"key":"2022060801183960700_BIB27","doi-asserted-by":"crossref","unstructured":"Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol\u20081999;162:5037\u201340.","DOI":"10.4049\/jimmunol.162.9.5037"},{"key":"2022060801183960700_BIB28","doi-asserted-by":"crossref","unstructured":"Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol\u20082007;125:76\u201387.","DOI":"10.1016\/j.clim.2007.07.005"},{"key":"2022060801183960700_BIB29","doi-asserted-by":"crossref","unstructured":"Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells in pregnancy and cancer. Front Biosci\u20082008;13:2275\u201389.","DOI":"10.2741\/2841"},{"key":"2022060801183960700_BIB30","doi-asserted-by":"crossref","unstructured":"Marx J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science\u20082008;319:154\u20136.","DOI":"10.1126\/science.319.5860.154"},{"key":"2022060801183960700_BIB31","doi-asserted-by":"crossref","unstructured":"Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res\u20082007;67:10019\u201326.","DOI":"10.1158\/0008-5472.CAN-07-2354"},{"key":"2022060801183960700_BIB32","doi-asserted-by":"crossref","unstructured":"Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res\u20082007;67:11021\u20138.","DOI":"10.1158\/0008-5472.CAN-07-2593"},{"key":"2022060801183960700_BIB33","doi-asserted-by":"crossref","unstructured":"Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood\u20082008;111:219\u201328.","DOI":"10.1182\/blood-2007-04-086835"},{"key":"2022060801183960700_BIB34","doi-asserted-by":"crossref","unstructured":"He Y, Zhang J, Donahue C, Falo LD, Jr. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity\u20082006;24:643\u201356.","DOI":"10.1016\/j.immuni.2006.03.014"},{"key":"2022060801183960700_BIB35","doi-asserted-by":"crossref","unstructured":"Spaner DE, Astsaturov I, Vogel T, et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer\u20082006;106:890\u20139.","DOI":"10.1002\/cncr.21669"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/8\/3\/692\/1883196\/692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/8\/3\/692\/1883196\/692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:04:56Z","timestamp":1684922696000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/8\/3\/692\/93368\/Potent-induction-of-B-and-T-cell-immunity-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,3,13]]},"published-print":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-08-0769","relation":{},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,1]]}}}